Drugs in Focus: The Use of Racecadotril in Paediatric Gastrointestinal Disease.

Data de publicació: 01/02/2020 Data Ahead of Print: 26/11/2019

Autors de IIS La Fe

• 

  Carmen Ribes Koninckx

  Autor

Autors aliens a IIS La Fe

• Pienar C
• Benninga MA
• Broekaert IJ
• Dolinsek J
• Mas E
• Miele E
• Orel R
• Thomassen RA
• Thomson M
• Tzivinikos C
• Thapar N

Grups d'Investigació

• Enfermedad celíaca e Inmunopatología digestiva

  

  Leader

  Carmen Ribes Koninckx

Abstract

Acute diarrhoea is a leading cause of morbidity and mortality in the paediatric population. Racecadotril is an antisecretory drug recommended as an adjuvant anti-diarrhoeal treatment.In the small bowel, the enzyme neutral endopeptidase (NEP) inhibits the action of enkephalins, which prevent water and electrolyte hypersecretion. By inhibiting NEP, racecadotril allows enkephalins to exhibit their antisecretory effects. Consequently, racecadotril reduces the secretion of water and electrolytes in the small intestine, without having an effect on intestinal motility. No serious adverse events related to racecadotril have been reported.Racecadotril has proven its efficacy as an adjuvant anti-diarrhoeal drug with a good safety profile. Its addition to oral rehydration solution (ORS) appears clinically beneficial and potentially leads to health care savings.

Keywords

• adjuvant; gastroenteritis; racecadotril